

2021 Fall Therapeutics Seminar Agenda

Day 1 (CE Credit Day 1 = 8 hours)

7:55 – 8:00 am

Activity Overview, James Wheeler, PharmD, BCPS

8:00 – 9:00 am

Pulmonary Potpourri: Updates in Community Acquired Pneumonia, Chronic Obstructive Pulmonary Disease, and Asthma

Joe Swanson, PharmD, FCCM, BCPS

9:05 – 10:05 am

Heart Failure Update

Kelly Rogers, PharmD, BCCP, FCCP, FACC

10:10 – 11:10 am

Make It or Break It: Optimizing Osteoporosis Management

Sarah Darby, PharmD, BCPS

11:15 – 12:15 pm

Rural Health and Pharmacy Practice: An Overview

Tyler Melton, PharmD, MPH, BCPS

12:10 – 1:00 pm

Lunch break

1:00 – 5:10 pm (to include two 5 minute breaks)

Recent Pharmacotherapeutic Developments:

Pharmacology and Therapeutics of Recently Introduced Drugs

Kelsey Frederick, PharmD

Recent Pharmacotherapeutic Developments: News you can use!

James Wheeler, PharmD, BCPS

5:10 pm: Adjournment

Day 2 (CE Credit Day 2 = 7 hours)

7:55 – 8:00 am

Activity Overview, James Wheeler, PharmD, BCPS

8:00 – 9:00 am

Update on Care for People Living with HIV/AIDS

Ted Corey, PharmD, PhD

9:05– 10:05 am CST

Role of technology and innovation practices in improving pharmacy quality measures and medication adherence

Karl Kodweis, PharmD

10:10 – 11:10 am CST

Hot Topics in Nephrology

Benjamin Duhart, PharmD, MS

11:15 – 12:15 pm

The Pharmacist as Public Health Provider

Rachel Barenie, PharmD, JD, MPH

12:15 – 1:00 pm

Lunch break

1:00 – 2:30 pm

Emerging Concepts in Infectious Diseases

Brandon Hawkins, PharmD, BCIDP

2:35 – 4:05 pm

Substance Use Disorders: An Update

Rachel Barenie, PharmD, JD, MPH

Target Audience – This activity is primarily intended for pharmacists and technicians from all practice settings. No prerequisites required.

Educational Objectives:

Upon completion of these activities, the participant should be able to:

Pulmonary Potpourri: Updates in Community Acquired Pneumonia, Chronic Obstructive Pulmonary Disease, and Asthma

UAN: 0064-0000-21-054-L01-P&T (1 hour)

Pharmacist Objectives:

- Summarize select changes to the community acquired pneumonia, COPD, and asthma guidelines
- Contrast antibiotic recommendations based on community acquired pneumonia severity and patient risk factors
- Interpret guideline recommendations for duration of therapy
- Assess the recommendation regarding pharmacist-led interventions and adherence
- Evaluate new medication recommendation pathways/tracks in community acquired pneumonia, COPD, and asthma

Technician Objectives:

- Summarize select changes to community acquired pneumonia, COPD, and asthma guidelines
- List antibiotics used in community acquired pneumonia
- Discuss duration of therapy for treatment of community acquired pneumonia
- Discuss recommendations regarding pharmacist led interventions and adherence

Heart Failure Update

UAN: 0064-0000-21-055-L01-P&T (1 hour)

Pharmacist Objectives:

- Review appropriate guideline directed medical therapy options for the treatment of HFrEF
- Describe the recent guideline updates for the treatment of HFrEF
- Discuss the new universal definition of heart failure consensus statement
- Explain where new therapies fit into the decision pathway for treatment
- Recognize future therapies on the horizon for HFrEF

Technician Objectives:

- Review recent guideline updates for the treatment of heart failure
- Identify new medications that are being prescribed and utilized for the treatment of heart failure
- Discuss the new universal definition of heart failure consensus statement

Make It or Break It: Optimizing Osteoporosis Management

UAN: 0064-0000-21-056-L01-P&T (1 hours)

Pharmacist Objectives:

- Review counseling points for the prevention and treatment of osteoporosis
- Describe updated recommendations included in the 2020 AACE/ACE Clinical Practice Guidelines
- Identify appropriate use of pharmacologic therapies for high risk and very high risk patients
- Discuss potential pharmacist roles in the management of osteoporosis

Technician Objectives:

- Review counseling points for the prevention and treatment of osteoporosis
- Describe updated recommendations included in the 2020 AACE/ACE Clinical Practice Guidelines
- Assist pharmacists in identifying appropriate use of pharmacologic therapies for high risk and very high risk patients

Rural Health and Pharmacy Practice: An Overview

UAN: 0064-0000-21-057-L01-P&T (1 hour)

Pharmacist Objectives:

- Define rural and social determinates of health
- Identify and describe rural health disparities and contributing social factors
- Discuss principles to apply in pharmacy practice settings and during patient interactions
- Identify areas of opportunity at your practice site to overcome unique barriers related to rural health

Technician Objectives:

- Define rural and social determinates of health
- Identify and describe rural health disparities and contributing social factors
- Discuss principles to apply in pharmacy practice settings and during patient interactions
- Identify areas of opportunity at your practice site to overcome unique barriers related to rural health

Recent Pharmacotherapeutic Developments

UAN: 0064-0000-21-058-L01-P&T (4 hours)

Pharmacist Objectives:

- Inform patients and prescribers of the pharmacological and therapeutic application(s) of existing drugs
- Identify the role of efficacy and cost of newly approved medications in comparison to existing agents.
- Discuss safety profiles and potential adverse drug reactions of newly introduced drugs
- Formulate a process to adequately inform patients and prescribers of the pharmacological and therapeutic application(s) of select recently introduced drugs
- Identify essential information to counsel patients on changes in the therapeutic application(s) of existing drugs and alternative therapies

Technician Objectives:

- List the primary use of drugs introduced in 2020
- Identify the role of cost of newly approved medications compared to existing agents
- Identify basic information on the pharmacological and therapeutic application(s) of select recently introduced drugs
- Identify essential information to assist the pharmacist in counseling patients on changes in the therapeutic application(s) of existing drugs and alternative therapies

Update on Care for People Living with HIV/AIDS**UAN: 064-0000-21-059-L01-P&T (1 hour)****Pharmacist Objectives:**

- Describe recent guideline updates in HIV-1
- Discuss recently approved agents and their role in treatment
- Review indications and medications for pre-exposure prophylaxis for people at risk of HIV acquisition
- Identify and assess clinically significant drug interactions between antiretroviral agents and concomitant drug therapy

Technician Objectives:

- Describe recent guideline updates in HIV-1
- Discuss recently approved agents and their role in treatment
- Review indications and medications for pre-exposure prophylaxis for people at risk of HIV acquisition

Role of technology and innovation practices in improving pharmacy quality measures and medication adherence**UAN: 0064-0000-21-060-L04-P&T (1 hour)****Pharmacist Objectives:**

- Review current trends on medication non-adherence in cardiovascular disease and the cost on the overall healthcare system
- Define pharmacy-specific quality improvement measures, with regards to adherence and medication synchronization
- Identify methods and strategies to utilize recent technological advancements to optimize pharmacy-quality metrics

Technician Objectives:

- Review current trends on medication non-adherence in CVD and the cost on the overall healthcare system
- Define pharmacy-specific quality improvement measures, with regards to adherence and medication synchronization
- Identify methods and strategies to utilize recent technological advancements to optimize pharmacy-quality metrics

Hot Topics in Nephrology**UAN: 0064-0000-21-061-L01-P&T (1 hour)****Pharmacist Objectives:**

- Explain the role of sodium-glucose cotransporter-2 (SGLT-2) inhibitors for patients with chronic kidney disease
- Review the mechanism of action of SGLT-2 inhibitors for limiting the progression of kidney disease
- Identify direct oral anticoagulants that are used in patients with chronic kidney disease

Technician Objectives:

- Explain the role of sodium-glucose cotransporter-2 (SGLT-2) inhibitors for patients with chronic kidney disease
- Review the mechanism of action of SGLT-2 inhibitors for limiting the progression of kidney disease
- Identify direct oral anticoagulants that are used in patients with chronic kidney disease

The Pharmacist as Public Health Provider

UAN: 0064-0000-21-062-L04-P&T (1 hour)

Pharmacist Objectives:

- Define 3 types of public health prevention
- Describe evidence-based, pharmacy-related public health interventions
- Identify a public health resource in your community to support patient care

Technician Objectives:

- Define 3 types of public health prevention
- Describe evidence-based, pharmacy-related public health interventions
- Identify a public health resource in your community to support patient care

Emerging Concepts in Infectious Diseases

UAN: 0064-0000-21-063-L01-P&T (1.5 hours)

Pharmacist Objectives:

- Describe novel therapeutic options for the treatment and prevention of HIV
- Identify guideline updates in the management of Clostridium difficile infections
- List considerations for the selection of oral antibiotics in serious infections
- Discuss shortened durations of therapy for select infectious disease states
- Explain the rationale for dose optimizations in specific disease states or settings

Technician Objectives:

- List novel therapeutic options for the treatment and prevention of HIV
- Identify guideline updates in the management of Clostridium difficile infections
- Explain the rationale for dose optimizations in specific disease states or settings

Substance Use Disorders: An Update

UAN: 0064-0000-21-064-L01-P&T (1.5 hours)

Pharmacist Objectives:

- List the diagnostic criteria for a substance use disorder
- Identify the top 3 most prevalent substance use disorders
- Discuss evidence-based treatment options
- Outline recent updates to treatment guidelines
- Describe opportunities to incorporate non-stigmatizing language into everyday practice

Technician Objectives:

- Identify the top 3 most prevalent substance use disorders
- Discuss evidence-based treatment options
- Describe opportunities to incorporate non-stigmatizing language into everyday practice



Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of these knowledge-based activities will provide a statement for up to 15 hours of CPE credit: 8 contact hours of credit (0.8 CEU) on day #1 and 7 contact hours of credit (0.7 CEU) on day #2. Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity; and, 4) completing all self-assessment instruments and CE credit submission form. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

NABP e-PROFILE ID NUMBER: Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Knowledge

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Participating Faculty:

Joe Swanson, PharmD, FCCM, BCPS
Kelly Rogers, PharmD, BCCP, FCCP, FACC
Sarah Darby, PharmD, BCPS
Tyler Melton, PharmD, MPH, BCPS
Kelsey Frederick, PharmD
James Wheeler, PharmD, BCPS
Ted Corey, PharmD, PhD
Karl Kodweis, PharmD
Benjamin Duhart, PharmD, MS
Brandon Hawkins, PharmD, BCIDP
Rachel Barenie, PharmD, JD, MPH

Financial disclosures: None

How to earn credit: Participants must complete the activity as described above in the Credit Designation Statement.

In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement: The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Questions?

If you have questions regarding this CPE activity, please call the Office of Continuing Education at (865) 974-6605, e-mail: jwheele4@uthsc.edu or refer to our web site: www.uthsc.edu/pharmacy/ce . Please contact the office of continuing education if you need special accommodations such as sight, hearing or access at this seminar.

Tuition

There is a \$30 fee for any returned check. Refunds, less a \$20 administrative fee, will be given only if the College of Pharmacy receives notification of cancellation prior to 10 a.m. (EST) on the Wednesday prior to the scheduled seminar. Day-of registrants will be charged an additional fee.

In compliance with a new UT policy, the College can no longer accept credit cards via phone, fax, or mail. Credit cards are acceptable for online registration only.

How to Register

We encourage all participants to **pre-register** to ensure space to accommodate your participation.

Provide the information requested on the registration form and pre-register via our online portal: www.uthsc.edu/pharmacy/ce, click on "Online Seminar Enrollment"

Grievance Policy

A participant, sponsor, faculty member or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by the UTCOP may contact the Associate Dean for Continuing Education in writing, by email jwheele4@uthsc.edu by phone (865) 974-6605. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, you may appeal your grievance to the Dean of the College of Pharmacy for a second level of review.